Celcuity Inc. (CELC)
| Market Cap | 2.98B -30.6% |
| Revenue (ttm) | n/a |
| Net Income | -256.02M |
| EPS | -4.72 |
| Shares Out | 49.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 730,854 |
| Open | 64.85 |
| Previous Close | 64.37 |
| Day's Range | 60.40 - 64.87 |
| 52-Week Range | 53.54 - 151.02 |
| Beta | 0.13 |
| Analysts | Strong Buy |
| Price Target | 150.85 (+149.05%) |
| Earnings Date | Nov 5, 2026 |
About CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $150.85, which is an increase of 149.05% from the latest price.
News
Celcuity Transcript: Stifel 2026 Healthcare Conference 2026
Early launch access metrics were strong, while positive phase III results and first-line data support a broad opportunity. Key milestones include the mutant sNDA review, prostate phase II completion in 2027 and expanded manufacturing capacity.
Celcuity Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
REVTORPYK launch is gaining account access, while mutant and first-line breast-cancer programs broaden the opportunity. Prostate Phase II is planned for H1 2027, and supply is expected to cover 2027 demand.
Celcuity announces FDA acceptance of sNDA for Revtorpyk
Celcuity (CELC) announced that the FDA has accepted for review its supplemental new drug application, or sNDA, for Revtorpyk for the treatment of patients with hormone receptor positive, human epiderm...
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of ...
Celcuity price target lowered to $150 from $155 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Celcuity (CELC) to $150 from $155 and keeps a Buy rating on the shares following the Q3 report.
Celcuity price target lowered to $135 from $150 at Stifel
Stifel lowered the firm’s price target on Celcuity (CELC) to $135 from $150 and keeps a Buy rating on the shares.
Celcuity price target lowered to $169 from $171 at Guggenheim
Guggenheim analyst Brad Canino lowered the firm’s price target on Celcuity (CELC) to $169 from $171 and keeps a Buy rating on the shares.
Celcuity Earnings Call Transcript: Q3 2026
REVTORPYK’s launch began with broad account engagement, pathway inclusion and payer coverage. Q3 loss widened amid commercialization spending, while $642.7M in cash and investments supports operations through 2029.
Celcuity Earnings release: Q3 2026
Celcuity released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Celcuity Quarterly report: Q3 2026
Celcuity has published its Q3 2026 quarterly earnings report on November 5, 2026.
Celcuity reports Q3 EPS ($1.21), consensus ($1.53)
“Our commercial and medical affairs teams have laid the foundation for a strong launch over the past few years, and their efforts are paying off,” said Brian Sullivan, CEO and…
Celcuity To Participate in Upcoming Investor Conferences
MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tu...
Celcuity price target lowered to $151 from $173 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Celcuity (CELC) to $151 from $173 and keeps a Buy rating on the shares. Revtorpyk’s launch on September 30th was at the later…
Kazia Therapeutics initiated with a Buy at Needham
Needham initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $27 price target. The recent approval of Celcuity’s (CELC) IV administered Revtorpyk in 2nd line WT PI3K HR+/HER2-…
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of ...
Celcuity announces results from PIK3CA cohort of Phase 3 VIKTORIA-1
Celcuity (CELC) announced new subgroup analyses from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study evaluating gedatolisib in patients with HR+/HER2- locally advanced or metastatic breast ca...
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases
Celcuity announces updated results from gedatolisib trial at ESMO
Celcuity (CELC) announced updated clinical results from the Phase 1b/2 study evaluating gedatolisib in patients with metastatic castration-resistant prostate cancer, or mCRPC. These data were presente...
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone
Cantor starts Celcuity at Overweight on multi-billion sales potential
Cantor Fitzgerald initiated coverage of Celcuity (CELC) with an Overweight rating and $140 price target Celcuity is a commercial-stage oncology company that recently launched its first product, Revtor...
Celcuity initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Li Watsek initiated coverage of Celcuity (CELC) with an Overweight rating and $140 price target
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA...
Celcuity appoints Gryska to Board of Directors
Celcuity (CELC) announced the appointment of David Gryska to its Board of Directors. Throughout the past 25 years, Gryska has served on the Boards of eight public biotechnology companies and…
Celcuity Appoints David Gryska To Its Board Of Directors
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board
Celcuity announces REVTORPYK is now commercially available in U.S.
Celcuity (CELC) announced that REVTORPYK is now commercially available in the United States for eligible patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, loc...